Management of immune-related adverse events and kinetics of response with ipilimumab.

By J. Weber, K. Kähler, A. Hauschild. Journal of Clinical Oncology, 2012

1,364 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/36f054434f23906989536f702f808d94d7e9e63c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Management of toxicities of immune checkpoint inhibitors. (2016, background): “the first few weeks on treatment whereas diarrhea and colitis tend to occur between weeks 5 and 10, liver toxicity from week 7 to 14 and hypophysitis after 6 weeks.[28] Most ipilimumab-related irAEs occur during the induction period.”
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. (2016, background): “ICBs generate atypical types of tumor responses [15] and have a specific toxicity profile which is challenging the historical oncologists’ practices [16].”
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. (2015, neutral): “), expansion of including skin, the gastrointestinal tract, adrenal glands, and liver (72, 73).”
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody (2014, background): “Hypophysitis usually develops 6 to 8 weeks after ipilimumab initiation (13) andoften requires prolongedor permanent hormonal replacement.”
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, background): “Symptoms appear, on average, after 9 weeks of treatment [18].”
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021, background): “The onset of these GI symptoms is most often in the range of 5-10 weeks after initiation of ICPi but can occur or recur months after discontinuation of immunotherapy.(26,66) Furthermore, with an increase in PD-1/PD-L1 antibodies given with cytotoxic CTX, a pattern of early-onset diarrhea (within 1-2”
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (2017, background): “blockade is associated with immune-related adverse events (irAE) [6, 7].”
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017, background): “Onset of skin irAEs typically occurs within days or weeks of treatment [38] although onset may be de-”